Client Success: Healthcare Transaction Support to Assess Value from Different Perspectives
THE SITUATION: A healthcare company with a portfolio of products in development for treating cardiac conditions was fielding investor interest for a potential acquisition. The company wanted to weigh the relative merits of raising additional equity financing versus exploring multiple M&A offers, as these initial discussions indicated a price range that did not fully reflect […]
Client Success: Mandatory Adoption of ASC 842 – Incremental Borrowing Rate Analysis for Private Biotech
The Situation: Adoption of ASC 842 – Lease Accounting is mandatory for all private companies for fiscal years beginning after December 15, 2021. To comply with this mandatory adoption requirement, a privately held, clinical stage biotech company needed to understand a reasonable discount rate for multiple lease agreements. The company requested an estimated borrowing rate […]
Client Success: Navigating Strategic Investment in Healthcare Technology
THE PROBLEM: A healthcare technology company that sells its FDA 510(k) approved device and supporting dashboarding and analytic tools to hospitals was in the midst of a capital raising effort involving a one-on-one negotiation with an existing strategic partner. The company received from the strategic partner a “low-ball” valuation. The company’s management team and board […]
Client Success: Incremental Borrowing Rate Analysis for Publicly Traded, Clinical Stage Biotech
THE PROBLEM: A publicly traded clinical stage biotech company needed to understand the correct implied discount rate for a lease agreement in accordance with ASC 842 rules. THE SOLUTION: ASC 842 has specific rules relating to leases, including guidance on lease classification (operating versus financial) and how to discount a lessee’s lease payments to arrive […]
Why Valuation Matters in Early-Stage Life Sciences
“Value”, the outcome of a thorough valuation analysis, is ultimately what parties agree to. Sometimes this seems a rational outcome, other times an irrational one. The reality is that a life sciences or healthcare technology company’s valuation often results from the ability or inability to create an effective bidding process and to persuade/anchor a strategic […]
Adaptive Valuation Approaches in Life Sciences and Healthcare
In finance, theories about the efficiency of markets have been both extraordinarily elegant and disastrously wrong on many occasions. These so-called efficient markets concepts have brought about interesting tools like the Capital Asset Pricing Model and Black-Scholes or Cox-Ross-Rubinstein binomial lattice models as tools for understanding how to assess a company’s cost of capital or […]
Client Success: Derivatives Valuation for pre-IPO Biotechnology Company
THE PROBLEM: A development stage biotechnology company (considering an IPO in the near future) entered into a series of financings which required the valuation of components of the financings deemed to be a derivative for financial reporting purposes. THE SOLUTION: RNA worked with the company and their Big 4 auditor to develop a Monte Carlo […]
Client Success: Valuation Support for Licensing Transaction – Novel Cancer Therapy
THE PROBLEM: Publicly traded late-stage therapeutics company negotiates with, and enters into, collaboration / license arrangement with a big pharma partner. THE SOLUTION: Forecasting, market research, modeling and transaction support combined with resultant collaboration agreement accounting analyses. “You were a great support for us, responsive and knowledgeable. Thank you!” CFO “You are my top go […]
Client Success: Portfolio Valuation for LPs of $1B + Healthcare-Focused PE Firm
THE PROBLEM: Two of the largest pension funds in the world required an independent valuation assessment of the portfolio of a multi-billion dollar life science/ healthcare private equity fund. THE SOLUTION: Robust research, forecasting, modeling, comp analysis and valuation analytics to determine reasonableness of value indications. “We love working with you. You actually know what […]
